Genome editing company CRISPR Therapeutics nets $52mm in IPO
CRISPR Therapeutics AG (genome editing focused on CRISPR/Cas9-based therapeutics) netted $52mm in its initial public offering of 4mm shares at $14 (down-sized and below the anticipated price range) on the Nasdaq. Concurrently, the company raised $35mm through the sale of 2.5mm shares to development partner Bayer through a private placement offering.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.